RPL36AP36

Across TCGA pan-cancer cohorts, RPL36AP36 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RPL36AP36’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL36AP36 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL36AP36 is over-expressed in tumor, although a few such as LUSC and READ show the opposite, repressed pattern.

KIRC, BLCA, and LUSC are the cancer types where RPL36AP36 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL36AP36 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.256	<.001	7	view →
BLCA	All	III,IV	+0.210	.002	5	view →
LUSC	Male	All	−0.164	.003	2	view →
READ	All	II,III,IV	−0.405	.023	1	view →
LUAD	Female	II,III,IV	−0.173	.040	1	view →
BRCA	Female	All	−0.070	.042	1	view →
THCA	All	All	+0.069	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RPL36AP36–KIRC

Open the KIRC breakdown →